Jet Life Penny Stocks Top Five Stocks: MWIP, ERBB, EXLA, HEB, AMBS
Stamford, CT -- (ReleaseWire) -- 12/21/2012 --Jet Life Penny Stocks Newsletter Announces Top Five Stocks for Friday 12/21/12.
MWIP: MediSwipe Inc. MediSwipe Inc., formerly Cannabis Medical Solutions Inc. offers a transaction processing and security solutions for the medical and healthcare industries, using traditional, Internet Point-of-Sale (POS), e-commerce and mobile (wireless) payment solutions. The Company's electronic payment processing suite of services will enable clients to accept all credit cards, in store or online, debit and automated teller machine (ATM) cards and ACH check drafts for payment whether a retail, service, mail-order or Internet merchant. The Company’s card-based processing services enable merchants to process both traditional card-present, or swipe, transactions, as well as card-not-present transactions. The Company also operates online payment processing services, gift and loyalty card program programs and prepaid debit cards for consumers through 800 Commerce Inc.
ERBB: The Tranzbyte Corporation is a driving force behind Altitude Organic Corporation. The company expects to continue its plan to acquire, hold, or spin out successful divisions in what has been described in previous news releases as "dividend farming." Companies that qualify that decide to become public on their own will agree to carve out shares for Tranzbyte and their ERBB shareholders once the spin-out is registered and publicly trading. This year, Tranzbyte acquired ProximaRF - a leading-edge company that produces a line of products supporting leading-edge RFID technology.
EXLA: Helmer Directional Drilling Corp. is a developmental-stage company. The Company’s principal business is to offer premium baseball cap type headwear for women and accessories. During the year ended December 31, 2011, the Company considered entering into the directional well drilling industry and changed its name from Exclusive App arel, Inc. to Helmer Directional Drilling Corp. As of December 31, 2011, the Company had not generated any significant revenues.
HEB: Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company's foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.
AMBS: Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.